A postdoctoral scientist in the HIV Molecular Pathogenesis Laboratory, Jacqueline has a keen interest in both virology and immunology, and aims to achieve better health for poor and vulnerable communities worldwide.
Her research interests include how HIV enters cells of the immune system with a focus upon alterations in the T cell subset HIV infects and in the differences in the pathogenesis of HIV subtype C compared to other HIV subtypes.
Jacqueline completed her PhD at Burnet Institute, investigating the stimulation and maintenance of T cell responses in acute hepatitis C. She commenced her postdoctoral training at the Peter MacCallum Cancer Centre investigating the trafficking of T cells to tumors in the immunotherapy laboratory.
Jacqueline chose to continue her postdoctoral training in Professor Gorry’s HIV Molecular Pathogenesis Laboratory at Burnet Institute. She was awarded an RMIT Vice Chancellor’s Postdoctoral Fellowship in 2015 and remains involved in a research capacity in the Gorry Laboratory at Burnet Institute.
- 2015: RMIT Vice Chancellor’s Postdoctoral Fellow
- 2015: Honorary Burnet Institute Fellow
- 2014: Victoria Fellow
- 2014: AFAS Fellow
- 2013: Adjunct Lecturer, Department of Infectious Diseases, Central Clinical School, Monash University, Australia
- 2015: Postdoctoral Fellow, Gorry Laboratory, School of Applied Sciences, RMIT University
- 2012-2015: Postdoctoral Fellow, HIV Pathogenesis Laboratory, Burnet Institute, Melbourne, Australia
- 2011: Postdoctoral Fellow, Immunotherapy Laboratory (Mike Kershaw/Phil Darcy), Peter MacCallum Cancer Centre, Melbourne, Australia
- 2009-2010: Demonstrator, Department of Immunology, Monash University, Melbourne, Australia
- 2007-2010: Part-time Research Assistant, Ffrench Laboratory, Burnet Institute, Australia
- 2004-2007: Research Assistant, Viral Immunology Laboratory, Burnet Institute, Australia
- 2002-present: Golden Key International Honours Society
- 2011: Doctor of Philosophy, Department of Immunology, Monash University, Australia
- 2005: Master of Biotechnology, RMIT, Australia
- 2002: BSc (Hons), Monash University, Australia
- 2015: RMIT Vice Chancellor’s Postdoctoral Fellowship
- 2014: Victoria Fellowship
- 2014: Harold Mitchell Foundation Postgraduate Travel Fellowship
- 2014: Ian Potter Foundation Travel Grant
- 2014: HIV R4P Conference Scholarship
- 2014: AFAS Fellowship
- 2013: CASS Foundation Travel Grant
- 2012: Australasian Society of Immunology (ASI) Conference Oral Presentation Prize
- 2010: Viral Hepatitis Conference Scholarship
- 2009: Monash University Postgraduate Symposium Oral Presentation Prize
- 2009: Federation of Immunological Societies of Asia-Oceania (FIMSA) Scholarship
- 2009: Qiagen Hepatitis Research Medal - ACH2 Conference Presentation Prize
- 2009: Monash University Postgraduate Travel Grant
- 2009: Monash University, Department of Immunology Conference Scholarship
- 2009: Infectious Diseases Research Prize - Alfred Hospital Melbourne
- 2007-2011: NHMRC Dora Lush Biomedical PhD scholarship
- 2007: ACHV Young Investigator Travel Award
- 2006: ASHM Undergraduate and Junior Researcher Award
- 2006: Infectious Diseases Research Prize - Alfred Hospital Melbourne
- Analysis of clinical HIV-1 strains with resistance to maraviroc reveals strain-specific resistance mutations, variable degrees of resistance, and minimal cross-resistance to other CCR5 antagonists.
Flynn J, Ellenberg P, Duncan R, Ellett A, Zhou J, Sterjovski J, Cashin K, Borm K, Gray L, Lewis M, Jubb B, Westby M, Lee B, Lewin SR, Churchill M, Roche M, Gorry P
AIDS Res Hum Retroviruses. 2017 Aug; Epub ahead of print
- Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K, Jakobsen MR, Cashin K, Flynn JK, Ellenberg P, Ostergaard L, Lee B, Churchill MJ, Roche M, Gorry PR
Retrovirology. 2016 Nov; 13(1):74
- Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes.
Roche M, Borm K, Flynn JK, Lewin SR, Churchill MJ, Gorry PR
Curr Top Med Chem. 2016 Jan; 16(10):1091-1106
- Differences in coreceptor specificity contribute to alternative tropism of HIV-1 subtype C for CD4 + T-cell subsets, including stem cell memory T-cells.
Cashin K, Paukovics G, Jakobsen MR, Ostergaard L, Churchill MJ, Gorry PR, Flynn JK
Retrovirology. 2014 Nov; 11(1):97
- Is the central nervous system a reservoir of HIV-1?
Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ
Curr Opin HIV AIDS. 2014 Sep; 9(6):552-558
- Stem memory T cells (TSCM)—their role in cancer
and HIV immunotherapies.
Flynn JK, Gorry PR
Clin Translat Immunol. 2014 Jul; 3:e20
- Quantifying Susceptibility of CD4+ Stem Memory T-Cells to Infection by Laboratory Adapted and Clinical HIV-1 Strains.
Flynn JK, Paukovics G, Cashin K, Borm K, Ellett A, Roche M, Jakobsen MR, Churchill MJ, Gorry PRy
Viruses. 2014 Feb; 6(2):709-726
- Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.
Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M
Hepat Mon. 2014 Jan; 14(1):e14678
- Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy.
Christel Devaud, Jennifer A Westwood, Liza B John, Jacqueline K Flynn, Sophie Paquet-Fifield, Connie Pm Duong, Carmen Sm Yong, Hollie J Pegram, Steven A Stacker, Marc G Achen, Trina J Stewart, Linda A Snyder, Michele Wl Teng, Mark J Smyth, Phillip K Darcy, Michael H Kershaw
Mol Ther. 2013 Sep; Epub ahead of print
- Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.
Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR
Retrovirology. 2013 Sep; 10(1):98
- Longitudinal analysis of CCR5 and CXCR4 usage in a cohort of antiretroviral therapy-naive subjects with progressive HIV-1 subtype C infection.
Jakobsen MR (equal contributor), Cashin K (equal contributor), Roche M, Sterjovski J, Ellett A, Borm K, Flynn J, Erikstrup C, Gouillou M, Gray LR, Saksena NK, Wang B, Purcell DF, Kallestrup P, Zinyama-Gutsire R, Gomo E, Ullum H, Østergaard L, Lee B, Ramsland PA, Churchill MJ, Gorry PR
PLoS One. 2013 Jun; 8(6):e65950
- Maintenance of Th1 HCV-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group.
J Gastroenterol Hepatol. 2013 May; 28(11):1170-1781
- A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR
Retrovirology. 2013 Apr; 10(1):43
- The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Lee B, Churchill MJ, Gorry PR, Roche M
Virology. 2013 Apr; 442(1):51-58
- Impaired HCV-specific IFN-gamma responses in individuals with HIV who acquire HCV infection correlate with levels of CD4 cells.
Flynn JK, Dore GJ, Matthews G, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; on behalf of the ATAHC Study Group.
J Infect Dis. 2012 Sep; 206(10):1568-1576
- Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
Liza B John, Linda J Howland, Jacqueline K Flynn, Alison C West, Christel Devaud, Connie P Duong, Trina J Stewart, Jenny A Westwood, Z Sheng Guo, David L Bartlett, Mark J Smyth, Michael H Kershaw, Phillip K Darcy
Cancer Res. 2012 Apr; 72(7):1651-1660
News Articles (7)